CASTLE BIOSCIENCES INC·4

Sep 7, 5:26 PM ET

Spiess Bernhard E. 4

4 · CASTLE BIOSCIENCES INC · Filed Sep 7, 2021

Insider Transaction Report

Form 4
Period: 2021-09-02
Spiess Bernhard E.
Chief Operating Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2021-09-02$2.39/sh+6,412$15,32528,963 total
  • Sale

    Common Stock

    2021-09-02$76.14/sh5,889$448,38815,036 total
  • Sale

    Common Stock

    2021-09-02$75.24/sh8,038$604,77920,925 total
  • Exercise/Conversion

    Common Stock

    2021-09-02$1.92/sh+8,989$17,25922,551 total
  • Sale

    Common Stock

    2021-09-02$77.29/sh1,474$113,92513,562 total
  • Exercise/Conversion

    Stock option (right to buy)

    2021-09-028,9895,889 total
    Exercise: $1.92Exp: 2026-05-23Common Stock (8,989 underlying)
  • Exercise/Conversion

    Stock option (right to buy)

    2021-09-026,4122,304 total
    Exercise: $2.39Exp: 2028-05-09Common Stock (6,412 underlying)
Footnotes (6)
  • [F1]These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.
  • [F2]This transaction was executed in multiple trades at prices ranging from $74.59 to $75.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $75.60 to $76.45, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This transaction was executed in multiple trades at prices ranging from $76.70 to $77.63, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter.
  • [F6]25% of the 12,305 shares originally subject to the option vested on May 10, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    wf-form4_163104995353264.xmlPrimary

    FORM 4